New sublingual pill may help allergies

May 30, 2014 by Sarah Worth
Credit: Eric Younghans, USF Health Office of Communications

Allergy sufferers are breathing a sigh of relief with the news that FDA-approved medications taken via a pill or drops under the tongue over the course of weeks – as opposed to a series of injections that might last years – are starting to hit the market.

The sublingual medication is as effective in some patients as injections, a standard course of treatment that has changed little in the past 100 years, said Richard F. Lockey MD, FACP, professor and director of the Division of Allergy and Immunology in the USF Health Morsani College of Medicine and holder of the Joy McCann Culverhouse Chair of Allergy and Immunology.

"Sublingual immunotherapy has been around for a long time but earlier concentrations were ineffective because they were in too small of doses to help patients build immunity," Dr. Lockey said. "These new standardized pills and drops are now in larger doses and have proven to be as effective in double-blind, controlled studies. These properly balanced studies showed a statistically significant benefit to patients."

The first pills and drops available this summer target certain grasses and ragweed. Formulas for cat, and other allergens should be available next, Dr. Lockey said, while those for oak, Bahia and Bermuda grasses, other trees, weeds and molds may take years.

Credit: Eric Younghans, USF Health Office of Communications

On-going clinical studies play into the pace for when the new sublingual immunotherapies become available. USF Health is a clinical site for the study related to dust mite allergies and continues to seek people allergic to dust mites to participate in the study, Dr. Lockey said. For more information about the dust mite study, call (813) 631-4024.

The number one allergen for Floridians is oak, Dr. Lockey said, so local will have to wait because it is not yet a standardized allergen and not available for sublingual immunotherapy.

Patients who might benefit from the new medications are those who are allergic to only one or two things, and only seasonally. Those allergic to multiple things, called polysensitized, would likely see bigger benefits from shots, Dr. Lockey said. That's because the serum used for injections can include concentrations for multiple allergens, creating a medication that is tailored to match each patient's allergies. The new sublingual immunotherapies target only single allergens, making them somewhat like "one-hit wonders."

But it also depends on where the person lives, he said. For example, people allergic to ragweed might be a candidate for the sublingual medications if they live up north, where ragweed blooms only seasonally. If they live in Florida, where ragweed is a year-round bloomer, they would not be prescribed the sublingual option.

The advantages for the new sublingual pills and drops are significant for patients, Dr. Lockey said, with time savings being the greatest. Sublingual immunotherapies are taken for about 12 weeks before the season begins and during the season for a patient's particular allergen, he said. Injections are typically given one or two times each week for three to five months and monthly thereafter for three to five years or more. In addition, sublingual medications can be self-administered once the patient has taken the first dose at a physician's office to monitor for adverse reactions. Injections require a visit to the physician's office.

One of the big hopes, Dr. Lockey said, is that the new easy-to-take medications might entice more people to find relief.

"Some cannot pursue shots because of time constraints," he said. "Sublingual immunotherapies can be given at home."

Explore further: Review article examines sublingual immunotherapy for treatment of allergic rhinitis and asthma

Related Stories

Review article examines sublingual immunotherapy for treatment of allergic rhinitis and asthma

March 26, 2013
In an examination of a type of treatment for allergic rhinitis and asthma that is used in Europe but not approved by the U.S. Food and Drug Administration, researchers found moderate strength in the evidence from previous ...

Study demonstrates that once-a-day pill offers relief from ragweed allergy symptoms

May 7, 2013
An international team of researchers, led by physician-scientists at Johns Hopkins, reports that a once-daily tablet containing a high dose of a key ragweed pollen protein effectively blocks the runny noses, sneezes, nasal ...

Oral drops can give kids needle-free relief from asthma, allergies

May 6, 2013
Allergy shots are commonly used to treat children with severe environmental allergies and asthma, but under-the-tongue drops may offer yet another beneficial—and stick-free—option for pediatric allergy sufferers, according ...

FDA panel considers first pill for ragweed allergy

January 28, 2014
(HealthDay)—There may be good news coming in the form of a pill for the millions of Americans who suffer from ragweed allergy.

Recommended for you

Genetic immune deficiency could hold key to severe childhood infections

July 18, 2017
A gene mutation making young children extremely vulnerable to common viruses may represent a new type of immunodeficiency, according to a University of Queensland researcher.

What are the best ways to diagnose and manage asthma?

July 18, 2017
What are the best ways to diagnose and manage asthma in adults? This can be tricky because asthma can stem from several causes and treatment often depends on what is triggering the asthma.

Large multi-ethnic study identifies many new genetic markers for lupus

July 17, 2017
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.

Study finds molecular explanation for struggles of obese asthmatics

July 17, 2017
A large, bouquet-shaped molecule called surfactant protein A, or SP-A, may explain why obese asthma patients have harder-to-treat symptoms than their lean and overweight counterparts, according to a new study led by scientists ...

Team identifies potential cause for lupus

July 14, 2017
Leading rheumatologist and Feinstein Institute for Medical Research Professor Betty Diamond, MD, may have identified a protein as a cause for the adverse reaction of the immune system in patients suffering from lupus. A better ...

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.